David Gerard Bourke

TL;DR: Developing this initial series of phenylaminopyrimidines led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-morpholinyl]amino]-4-pyrimidinyl]-benzamide).

TL;DR: In this paper, the authors proposed a thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 and combinations thereof such as JAK 1 and JAK 2.

TL;DR: In this article, N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases are described and used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative disease; viral diseases; metabolic diseases; and vascular diseases.

TL;DR: A maleimide derivative, where the central quinone between the pendant hydroxyquinones was replaced, was successfully synthesised and although it exhibited comparable enzyme inhibitory activity it had negligible HIV inhibitory cellular activity.

TL;DR: A small molecule non-nucleoside inhibitor of Hepatitis B Virus discovered during work on conocurvone derived naphthoquinone 'trimers' is also an inhibitor of hepatitis B Virus resistant to 3TC, a bench mark of nucleoside analogues active in the treatment of Hep atitis B virus.